Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

argenx

Immunology-focused biopharmaceutical company

Latest news about argenx

April 18 argenx

argenx presents VYVGART data at AAN 2026

New studies support broader use in MG subtypes and CIDP, including ocular MG and treatment-naïve patients. Plans sBLA submissions.
March 20 argenx

argenx announces Annual General Meeting on May 6, 2026

The meeting will occur at 13:00 CET in Amsterdam. It includes adoption of 2025 accounts, board appointments, re-appointments, and Jim Daly's retirement.
March 6 argenx

argenx presents new data at 2026 AAN Meeting

Data covers VYVGART in MG and CIDP, plus pipeline candidates. Highlights Phase 3 results for ocular MG and seronegative gMG.
February 26 argenx

argenx reports strong 2025 growth

Reached 19,000 patients globally in gMG and CIDP. Advances FcRn portfolio and Immunology Innovation Program toward Vision 2030 of 50,000 patients.

Today BioSpace

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer's disease.
May 2 Yahoo Finance

Argenx (ARGX) Outlook Improves on Autoimmune Pipeline Expansion

Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD...
April 30 Morningstar

Halozyme to Report First Quarter 2026 Financial and Operating Results

SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating...
April 28 NeurologyLive

Nipocalimab Shows Sustained Disease Control and Symptom Improvement in 2-Year Extension Study | NeurologyLive - Clinical Neurology News and Neurology Expert Insights

phase 3 head-to-head EPIC trial, will address whether the agent provides superior efficacy to efgartigimod (Vyvgart; argenx) in the latter part of efgartigimod treatment cycles...

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to argenx and other trending companies.